# TB-500 FAQ: Mechanism, Safety, Comparisons, and Legal Status

> TB-500 questions answered from the literature: what it is, how it works, whether it reduces inflammation, the BPC-157 comparison, the steroid myth, WADA status, and the FDA 503A category. Cited.

Direct answers, each cited where it makes a quantitative claim, and each keeping the fragment-versus-protein line visible.

## Definition and identity

### What is TB-500?
TB-500 is the synthetic, N-acetylated heptapeptide Ac-LKKTETQ corresponding to residues 17–23 of thymosin beta-4 — the actin-binding motif [1]. It is a research and veterinary-context chemical with no approved human indication [11].

### What does TB-500 stand for?
TB refers to thymosin beta-4 (Tβ4); TB-500 is a product and research designation for the synthetic Ac-LKKTETQ fragment of that protein. The number is a label, not a dose or concentration.

### What is TB-500 used for in research?
In animal and in-vitro studies, thymosin beta-4 and its actin-binding region are investigated for wound and tissue repair, cell migration, angiogenesis, cardiac and neurological repair, and anti-fibrotic effects [5].

### How does TB-500 work?
The LKKTETQ motif is thymosin beta-4's actin-binding region; the parent protein binds monomeric (G-) actin 1:1, regulating cytoskeletal dynamics, cell migration, angiogenesis, and survival signaling [1][2]. Whether the isolated 7-mer reproduces these at research doses is not established in humans.

### Is TB-500 a steroid?
No. TB-500 is a peptide fragment — seven amino acids, Ac-LKKTETQ — not a steroid [1]. Steroids share a four-ring lipid scaffold and act on nuclear hormone receptors; TB-500 is a short peptide carrying an actin-binding motif and works, if at all, through entirely different cytoskeletal and signaling biology.

## Mechanism and effects

### Does TB-500 reduce inflammation?
Full-length thymosin beta-4 inhibited TNF-α–induced NF-κB activation and IL-8 expression in vitro [13] and activates pro-resolving pathways [14] — the mechanistic basis for an anti-inflammatory effect; whether the isolated heptapeptide reproduces this in humans is unproven.

### Can TB-500 cause autoimmune reactions or affect the immune system?
Thymosin beta-4 is reported to modulate inflammatory and pro-resolving pathways rather than provoke autoimmunity [14], but there are no controlled human safety data for the TB-500 fragment to confirm immune effects either way.

### Does TB-500 work for muscle recovery?
Muscle-injury-induced Tβ4 acts as a myoblast chemoattractant in rodents, but a six-month mdx-mouse study found more regenerating fibers without gains in strength or cardiac function [5]. No controlled human exercise-recovery data exist for the fragment.

### Does TB-500 help wound healing?
Full-length thymosin beta-4 accelerated re-epithelialization, contraction, collagen deposition, and angiogenesis in animal wound models and topical ophthalmic trials [3][5]; human data for the fragment are absent.

### How long does TB-500 take to work?
No validated human timeline exists. In a rat wound model, full-length Tβ4 raised re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline [3], but animal kinetics do not translate to a human schedule.

### Can TB-500 help tendon and ligament repair?
Thymosin beta-4 has been studied in connective-tissue repair within its broad migration-and-angiogenesis profile [5], but there is no controlled human tendon or ligament data for the fragment.

### Does TB-500 affect the heart?
In mice, thymosin beta-4 activated PINCH–ILK–Akt survival signaling and improved cardiac function after coronary ligation [2]; systemic Tβ4 failed to attenuate ischemia-reperfusion injury in a porcine study, and human cardiac data are limited to a completed registered acute-MI trial [10].

### Does TB-500 have neuroprotective effects?
In a rat embolic-stroke dose-response study, intraperitoneal Tβ4 improved neurological function at 2 and 12 mg/kg but not at 18 mg/kg, with a modeled optimum near 3.75 mg/kg [4]. An injectable human stroke trial was withdrawn [11].

### What is the half-life of TB-500?
No validated human pharmacokinetic half-life exists for the heptapeptide. In the IV full-length Tβ4 Phase 1 study, half-life increased with dose [6]; anti-doping LC-MS work characterizes TB-500 for detection, not human PK.

## Safety and comparison

### What are the side effects of TB-500?
Human safety data for the fragment are scarce. Full-length Tβ4 was well tolerated to 1260 mg IV in a Phase 1 study [6]; the principal theoretical concern is the pro-angiogenic and pro-migratory tumor signal [5], and research-grade purity is a recurring issue.

### Does TB-500 cause cancer or promote tumor growth?
Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis; the same pro-migratory and pro-angiogenic properties that aid repair could theoretically support tumor progression [5]. This is an unresolved safety concern.

### Is TB-500 safe for long-term use?
There are no long-term human safety data for the TB-500 fragment. The longest controlled exposure is a 14-day IV Phase 1 study of full-length Tβ4 [6]; the tumor and angiogenesis signal makes chronic use an open question [5][12].

### Are there human clinical trials on TB-500?
There are no completed controlled trials of the TB-500 heptapeptide. Human data exist only for full-length thymosin beta-4: a randomized Phase 1 IV safety study [6] and topical ophthalmic trials [7]; a registered injectable acute-MI trial completed [10] and an early injectable stroke trial was withdrawn [11].

### What is the difference between TB-500 and BPC-157?
They are unrelated peptides studied separately. TB-500 is the Ac-LKKTETQ fragment of thymosin beta-4, an actin-binding peptide [1]; BPC-157 is a distinct gastric pentadecapeptide. Both are unapproved, WADA-relevant research compounds with mostly animal data.

## Legal and regulatory

### Is TB-500 legal?
TB-500 occupies a narrow status. It is not an FDA-approved drug, and FDA lists the LKKTETQ fragment as TB-500 and placed it in 503A Category 2 — bulk substances that may present significant safety risks — so it is not within FDA's enforcement-discretion policy for routine 503A compounding while that status stands [reg1][reg3]. It is supplied as a research and veterinary-context chemical, is WADA-prohibited in sport, and is a prescription medicine in some jurisdictions. "TB-500 (free base)" and "TB-500 acetate" are on the published agenda of the July 23–24, 2026 PCAC meeting as substances under evaluation — a scheduled discussion, not a change in status [reg2].

### Can you get TB-500 from a compounding pharmacy?
Legally compounded medications follow a defined pathway: a licensed prescriber evaluates a patient (telehealth can be the front-end channel), issues a patient-specific prescription, and a 503A pharmacy or 503B outsourcing facility compounds it — but only if the ingredient is eligible under the bulk-substance rules [reg3][reg4]. Because FDA placed TB-500 in Category 2, it is not eligible for routine 503A compounding while that status stands [reg4]. This is general information, not medical advice, and not an offer to supply anything.

### What is the FDA 503A status of TB-500?
FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 — substances that may present significant safety risks — effective with its September 29, 2023 nominated-substances update, citing concerns including potential immunogenicity for certain routes and a lack of important safety information [reg1]. Category 2 substances are not afforded FDA's enforcement discretion for 503A compounding [reg3]. The substance is on the July 2026 PCAC agenda for evaluation, which is a discussion and not a decision [reg2].

### Is TB-500 banned by WADA?
Yes. TB-500 and thymosin beta-4 fall under WADA prohibited peptide, growth-factor, and tissue-repair categories, banned in and out of competition, and are detectable by LC-MS anti-doping assays.

### Why is TB-500 associated with racehorses?
TB-500 has been encountered as a designer substance in equine sport, which is why the first validated LC-MS detection methods (limits of detection around 0.01–0.02 ng/mL) were developed in horses. It is prohibited in regulated racing.

---

A cinematic dark-folio reading of the thymosin beta-4 literature, kept honest about where the Ac-LKKTETQ fragment's human data stop — an editorial dossier, never a clinic and nothing dispensed.